logo
Titan Logix Corp. Reports Its Fiscal 2025 Q3 and YTD Financial Results

Titan Logix Corp. Reports Its Fiscal 2025 Q3 and YTD Financial Results

Yahoo16-07-2025
(In $000's of Canadian dollars except for shares and per share amounts)
Edmonton, Alberta--(Newsfile Corp. - July 16, 2025) - Titan Logix Corp., (TSXV: TLA) ("Titan" or the "Company"), a technology company specializing in mobile liquid measurement solutions, announces its interim results for the three- and nine-month periods ended May 31, 2025.
"We are on track to begin field trials of our new product line for the refined petroleum market by the end of the fiscal year," says Nick Forbes, CEO at Titan. "This will be a key enabler for our growth into new markets by delivering innovative technology with a proven track record."
The upcoming launch of our new product line, designed to meet specific customer needs in the refined fuels market, will drive new pilot trial and sales opportunities. Notably, the Company achieved CSA certification on its new FINCH display in the third quarter, and we are on track to begin field trials of the new product line by the end of the fourth fiscal quarter. This product, based on our proven TD-series platform, offers several key differentiators:
Reliable overfill protection and rack control, giving refined petroleum fleets flexibility in rack, and non-rack loading environments.
Enhanced safety and efficiency, displaying highly accurate liquid level measurement with improved performance over previous generation TD-series products.
A compelling value proposition for fleet operators through integration with Titan's cloud-connected digital strategy.
In parallel, Titan continued onboarding key dealer and OEM accounts into its Titan Install mobile application and Titan Portal back-office platform. These tools have been praised by channel partners for their intuitive design, ease of use, and modern capabilities. Our digital strategy remains a core differentiator, strengthening Titan's market position.
YTD & Q3 FISCAL 2025 HIGHLIGHTS
Revenues for the first nine months of fiscal 2025 were consistent with fiscal 2024 with only a modest decrease of $46 or 1% to $5,145 compared to $5,191 for the same period in fiscal 2024. However, revenues for the third quarter of fiscal 2025 decreased by $436 or 23% to $1,489 compared to $1,926 in the third quarter of fiscal 2024, as the uncertainty and threat of tariffs on sales to the Company's US market continued to have a negative impact in the current quarter.
Gross Profit through the first nine months of fiscal 2025 increased slightly by $29 to $2,635 or 51% of revenues compared to $2,606 or 50% of revenues in the comparative period. The increase in Gross Profit resulted from lower key manufacturing input costs and stronger US dollar when compared to the same period in fiscal 2024. Gross Profit decreased by $296 to $708 or 48% of revenue in the third quarter of fiscal 2025 compared to $1,004 or 52% of revenue in the same quarter of fiscal 2024 due mainly to reduced revenue volumes.
The performance of the CORE business, measured by Operating EBITDA(1), has increased by 22% through the first nine months of the fiscal 2025 to $968, compared to $792 through same period in fiscal 2024. Operating EBITDA(1) declined by $327 or 80% in the third quarter of fiscal 2025 however, with reported Operating EBITDA of $83 compared to $410 in the same period of fiscal 2024, a direct result of the reduced volume experienced in the third fiscal quarter compared to the third quarter of fiscal 2024.
Product research and development expenses increased by $201 to $999 in the current fiscal 2025 year compared to $798 in the same period of fiscal 2024, with the third quarter product research and development expenses increasing by $82 to $368 in the current fiscal quarter compared to $285 in the same quarter of fiscal 2024. The expenses incurred support the Company's diversification and growth into new markets.
The Company's net loss has improved by $153 to a net loss of $225 in the current fiscal year compared to a net loss of $378 in the same period of fiscal 2024, this decrease resulted from lower unrealized losses on marketable securities in the current year. The Company's net loss in the third quarter increased by $202 to a net loss of $421 compared to a net loss of $202 in the third quarter of fiscal 2024 due mainly to the current period reduction in volume experienced.
Financial Highlights SummaryThree months ended
Nine months ended
2025
2024
2025
2024
$
$
$
$
Revenue
1,489
1,926
5,145
5,191
Cost of sales
(782)
(922)
(2,510)
(2,584)
Gross profit
708
1,004
2,635
2,606
Gross margin (%)
48%
52%
51%
50%
Operating EBITDA (1)
83
410
968
892
Product research and development expenses (1)
(368)
(285)
(999)
(798)
EBITDA (1)
(285)
125
(31)
93
Net loss
(421)
(218)
(225)
(378)
EPS - Basic and Diluted
(0.01)
(0.01)
(0.01)
(0.01)
Financial Position
As at May 31, 2025
As at August 31, 2024
Working capital
$
15,345
$
14,139
Total assets
$
18,602
$
19,022
Long-term liabilities
$
494
$
600
Total equity
$
17,171
$
17,502
(1) See Non-IFRS measures below.
The Company's unaudited, condensed, consolidated interim financial statements and the management's discussion and analysis ("MD&A") which includes the Company's Business Outlook, for the three- and nine-month periods ended May 31, 2025, are available on SEDAR+ at www.sedarplus.ca and the Company's website, www.titanlogix.com.
NON-IFRS MEASURES
The Company uses certain measures in this MD&A that do not have a standardized meaning as prescribed by IFRS (International Financial Reporting Standards) and thus are prohibited from being disclosed in the consolidated financial statements. These measures, which are derived from information reported in the Company's consolidated financial statements, may not be consistent with similar measures presented and disclosed by other reporting issuers. However, management believes that this information provides increased insight into the Company's strategic plan to address the broader mobile liquid markets. Readers are cautioned that these Non-IFRS measures should not be construed as alternatives to other measures of financial performance calculated in accordance with IFRS.
The table below provides a reconciliation of the Company's EBITDA and Operating EBITDA to the Operating income (loss) before other items per the interim consolidated financial statements for the periods presented:
Fiscal Period Ended
Q3 2025
Q3 2024
YTD 2025
YTD 2024
Operating income (loss) before other items
(388)
2
(416)
(245)
Add: Depreciation and amortization
96
99
289
283
Add: Non-cash stock-based compensation
7
24
96
55
EBITDA
(285)
125
(31)
93
Add: Product research and development expenses (1)
368
285
999
798
Operating EBITDA
83
410
968
892
The table below, removes the recurring engineering expenses from the total to isolate the product research and development expenses excluded in Management's calculation of Operating EBITDA:
Fiscal Period Ended
Q3 2025
Q3 2024
YTD 2025
YTD 2024
Engineering, product research and development expenses
(396)
(333)
(1,088)
(949)
Less: Recurring engineering expenses
28
47
88
150
Product research and development expenses
(368)
(285)
(999)
(798)
(1) A detailed definition of these Non-IFRS measures can be reviewed in the Company's MD&A
About Titan Logix Corp.:
For over 25 years, Titan Logix Corp. has designed and manufactured mobile liquid measurement solutions to help businesses reduce risk and maximize efficiencies in bulk liquids transportation. Titan's TD Series of tank level monitors are a market leader in mobile fluid measurement, and are known for their high level of accuracy, rugged design, and solid-state reliability. Our solutions are designed for hazardous and non-hazardous applications, and we serve customers in a wide range of applications including petroleum, environmental solutions, chemical, and agriculture.
Founded in 1979, Titan Logix Corp. is a public company listed on the TSX Venture Exchange and its shares trade under the symbol TLA.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Readers are cautioned that the actual performance of the Company is subject to many risks and uncertainties and could differ materially from what is expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our Management Discussion and Analysis in respect of the year ended August 31, 2024, which is available at www.sedarplus.ca. In addition, the occurrence of pandemics, such as the outbreak of the novel coronavirus COVID-19 in any of the areas in which the Company, its customers or its suppliers operate could cause interruptions in the Company's operations. In addition, pandemics, natural disasters, or other unanticipated events could negatively impact the demand for, and price of, oil and natural gas which in turn could have a material adverse effect on the Company's business, financial condition, results of operations and cash flows. The forward-looking information contained in this press release is based on our current estimates, expectations, and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any time, whether a result of new information, future events or otherwise, except as required by applicable securities law
Contact Information:
Nick ForbesChief Executive OfficerPh: (403) 561-8095Email: invest@titanlogix.comwww.titanlogix.comTSX Venture, TLA
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259074
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates

Yahoo

time23 minutes ago

  • Yahoo

Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates

The global recombinant human hair keratin protein market is growing quickly as more people seek effective hair health solutions and advanced wound healing treatments, says a study published by Towards Healthcare a sister firm of Precedence Research. Ottawa, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The global recombinant human hair keratin protein market is on a strong growth trajectory, with revenues expected to climb into the hundreds of millions by 2034. This momentum is being fueled by a rising focus on hair health, a noticeable increase in bleeding disorder cases, and a wave of fresh investments pouring into biotechnology. Together, these factors are creating fertile ground for innovation and demand across multiple industries. Companies in North America, Asia-Pacific, and Europe are actively investing in research, driving innovations, and forming partnerships to open new market opportunities. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the recombinant human hair keratin protein market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. Market Overview & Potential Recombinant human hair keratin protein is a lab-engineered protein that replicates the structure and function of natural keratin in human hair. It is produced via recombinant DNA technology, resulting in a highly controlled and pure form of keratin that differs from traditional extracts. This makes it a valuable material for applications such as wound healing and hair care. Conventional keratin extraction methods can be inconsistent and may not yield pure products, whereas recombinant production ensures greater purity and enables precise control over the protein's amino acid sequence and structure, resulting in more predictable properties. Top Countries in Recombinant Human Hair Keratin Protein Market: United States Contribution: Leading the global market with strong demand for medical-grade recombinant keratin, supported by a robust biotech ecosystem and healthcare infrastructure. Strength: Advanced R&D capabilities and regulatory support for therapeutic and regenerative applications. China Contribution: Fastest-growing market, fueled by a rapidly expanding cosmetics and personal care sector. Strength: Strong domestic production capabilities, rising consumer awareness, and increasing investment in biotech innovations. Germany Contribution: Key contributor in Europe, especially in high-purity recombinant keratin for medical and cosmetic formulations. Strength: Expertise in biotechnology and demand for premium, high-performance personal care products. France Contribution: Strong market for cosmetic applications, particularly in haircare and skincare products incorporating natural bioactive ingredients. Strength: Sophisticated beauty industry and preference for sustainable, biologically derived ingredients. India Contribution: Emerging player in both medical and cosmetic applications of recombinant keratin. Strength: Large population base, rising demand for advanced hair and skin treatments, and growing domestic manufacturing activity. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growth Potential Responsible for The Growth of The Recombinant Human Hair Keratin Protein Market? The growth of the market is driven by the growing application in the biomedical field due to its biocompatibility, ability to promote cell growth, and biodegradability, which makes it ideal for various medical uses, driving the growth. The key applications, like tissue regeneration, drug delivery systems, and wound healing, are supporting the growth of the market. Other key drivers are biotechnology research due to the growing biotechnology sector, in personal care and cosmetics, and sustainable and ethical sourcing. Increasing incidence of chronic diseases, and government initiatives in R&D in life sciences research and development. What Are the Growing Trends Associated with the Recombinant Human Hair Keratin Protein Market? The technological advancements like innovation in synthetic biology and demonstration technology for the development of new and tailored properties, and more efficient production methods. Rising demand in the cosmetic sector for the development of hair care products for improving the shine, strengthening the damaged hair, and reducing the frizz increases the demand for the product. The growing biomedical applications, like in wound healing, tissue engineering, and drug delivery, fuel the demand for the product, supporting the growth. Shift towards sustainable and ethical products, like growing demand and interest in vegan and plant-based keratins, improves the market growth of the market. Increasing awareness and adoption due to the benefits offered and availability of the products make it a preferred choice, and increase the growth. What Is the Growing Challenge in the Recombinant Human Hair Keratin Protein Market? However, the recombinant human hair keratin protein market faces challenges including production issues, consistency concerns, and consumer perceptions. Although recombinant technology provides advantages like higher purity and specific amino acid composition, it also risks problems like misfolding, aggregation, and low yields. Additionally, high production costs, especially due to specialized equipment and chemicals, can hinder market growth. Consumer preferences for natural or plant-based products, along with safety and efficacy concerns regarding keratin treatments, could also limit market expansion. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Analysis How Did North America Dominate the Recombinant Human Hair Keratin Protein Market in 2024? North America led the recombinant human hair keratin protein market in 2023. Growth is driven by increased investments, collaborations, key industry players, and advanced R&D activities. The US and Canada are the primary markets, with companies like Novus Biologicals, Abcam Ltd., PROGEN, and OriGene contributing significantly. US government initiatives to promote biotech research further boost the market, complemented by over 130 recombinant proteins approved by the US FDA for clinical use. In the UK, industries are exploring innovative methods to enhance hair growth, quality, and reduce hair fall using recombinant human hair keratin protein. Additionally, rising awareness about hair health is fueling demand for these products. What Made Asia Pacific Significantly Grow in The Recombinant Human Hair Keratin Protein Market in 2024? Asia-Pacific is expected to grow the fastest in the recombinant human hair keratin protein market during the forecast period. Market growth is driven by increasing research and development activities, rising government funding, a growing number of bleeding disorder cases, favorable infrastructure, and lower costs. Recombinant keratin has been shown to promote skin wound healing and improve blood clotting. In China, about 65,000 people suffer from hemophilia, while India has the second-largest number of hemophilia cases worldwide, with 136,000 patients. The demand for products that support hair growth and reduce hair loss is rapidly increasing in China, South Korea, and Japan. Companies like Tsubaki use recombinant human keratin to develop luxurious hair treatments that attract beauty-conscious consumers. Become a valued research partner with us - Recent Developments In July 2024, Yuhan Corp, a South Korean pharmaceutical company, signed a comprehensive R&D collaboration agreement with ProGen. The collaboration was made to strengthen next-generation biologics and drug development research. In April 2024, Bio-Techne Corporation announced a strategic distribution agreement with Thermo Fisher Scientific. The agreement will distribute Bio-Techne's innovative products, such as antibodies, proteins, immunoassay kits, reagents, and enzymes, to laboratories and research institutions across Europe. Browse More Insights of Towards Healthcare: The global GMP grade cytokines market is valued at USD 2.54 billion in 2024, expected to rise to USD 2.79 billion in 2025, and anticipated to reach approximately USD 6.48 billion by 2034. This represents a steady growth trajectory at a CAGR of 9.84% from 2025 to 2034. The global recombinant proteins market is estimated at USD 3.36 billion in 2025 and is forecasted to climb to around USD 8.08 billion by 2034, expanding at a CAGR of 10.24% over the forecast period. The recombinant lysyl endopeptidase market was valued at USD 38 million in 2023 and is projected to reach USD 67.06 million by 2034, growing at a CAGR of 5.3% between 2024 and 2034. The global hair transplant market stands at USD 7.33 billion in 2024, rising to USD 8.87 billion in 2025, with projections indicating a surge to nearly USD 49.44 billion by 2034—signaling rapid expansion. The hair treatment drug market was worth USD 1.4 billion in 2023 and is anticipated to grow to USD 2.99 billion by 2034, recording a CAGR of 7.14% during 2024–2034. The global host cell protein testing market is valued at USD 2.37 billion in 2024, estimated to increase to USD 2.56 billion in 2025, and forecasted to hit USD 5.19 billion by 2034, with an expected CAGR of 8.17% from 2025 to 2034. The global protein expression technology market is pegged at USD 2.85 billion in 2024, projected to rise to USD 3.05 billion in 2025, and likely to reach USD 5.58 billion by 2034, reflecting a CAGR of 6.94% over the forecast timeline. The global proteinase K market is valued at USD 4.82 billion in 2024, forecasted to grow to USD 5.23 billion in 2025, and set to reach USD 10.93 billion by 2034, advancing at a CAGR of 8.54% between 2025 and 2034. The global cell-free protein expression market is valued at USD 315.03 million in 2024, expected to grow to USD 342.25 million in 2025, and projected to hit USD 716.26 million by 2034, expanding at a CAGR of 8.63% from 2025 to 2034. The global protein therapeutics market is calculated at USD 375.3 billion in 2024, projected to grow to USD 401.89 billion in 2025, and expected to reach USD 740.07 billion by 2034, advancing at a CAGR of 7.08% over the forecast period. Recombinant Human Hair Keratin Protein Market Key Players Abcam Limited Abbexa, Ltd. Bon Opus Biosciences Creative Diagnostics MyBioSource, Inc. Novus Biologicals OriGene PROGEN ProSpec Wuhan Huamei Biotech Co., Ltd. Regions Covered North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Rogers Communications selling data centre portfolio to InfraRed Capital Partners
Rogers Communications selling data centre portfolio to InfraRed Capital Partners

Yahoo

time23 minutes ago

  • Yahoo

Rogers Communications selling data centre portfolio to InfraRed Capital Partners

TORONTO — Rogers Communications Inc. has signed a deal to sell its portfolio of nine data centres to InfraRed Capital Partners. Financial terms of the sale were not immediately available. Under the agreement, Rogers will continue to sell data centre services on behalf of InfraRed and will provide network connectivity to the data centres. The deal does not include Rogers corporate data centres used for the company's network and IT purposes. Rogers says the transaction is part of its planned sale of real estate and non-core assets. Net proceeds are expected to be used to repay debt. InfraRed is part of the asset management business of Sun Life. This report by The Canadian Press was first published Aug. 14, 2025. Companies in this story: (TSX:RCI.B, TSX:SLF) The Canadian Press Sign in to access your portfolio

Cohere hires long-time Meta research head Joelle Pineau as its chief AI officer
Cohere hires long-time Meta research head Joelle Pineau as its chief AI officer

Yahoo

time23 minutes ago

  • Yahoo

Cohere hires long-time Meta research head Joelle Pineau as its chief AI officer

Investors once saw Canadian AI startup Cohere as a promising contender to challenge OpenAI and Anthropic in the race to build frontier AI models, with its backers pouring roughly $1 billion on their bet on CEO Aidan Gomez, who co-authored a seminal paper on LLMs when he was a 20-year-old Google intern. But Cohere's AI models have fallen behind the state-of-the-art, and its business hasn't scaled like its competitors. Now, the company is bringing in a veteran research leader to revamp its AI efforts: Cohere has hired Joelle Pineau, Meta's former VP of AI research who previously oversaw the tech giant's fundamental AI research (FAIR) lab. In her newly created Chief AI Officer role, Pineau will oversee AI strategy across Cohere's research, product and policy teams. A Canadian AI scientist and McGill Professor, Pineau helped guide the early development of Meta's open Llama AI models alongside Yann LeCun, a pioneer of neural networks. Pineau left Meta in May after nearly eight years with the company. For Cohere this is a big hire, and it is pinning its hopes on the veteran helping it with more research breakthroughs, improving its research and product pipeline, and recruiting top talent. The hire comes at a pivotal moment for Cohere: The company is reportedly seeking to raise up to $500 million at a $6.3 billion valuation — an impressive sum were the startup not competing with the likes of OpenAI, Google, Meta and Anthropic, whose war chests are worth dozens of billions each. But while its rivals are trying to develop AI systems that can match (or exceed) human performance on a wide variety of tasks, Cohere has a narrower focus. The startup primarily builds AI applications that can solve practical problems for enterprises and government agencies, emphasizing privacy and security. In an interview with TechCrunch, Pineau said Cohere's focus on real-world, enterprise applications is something she's excited about. 'A lot of players out there are quite singularly focused on AGI, superintelligence, and so on,' said Pineau, alluding to companies like her former employer, Meta, which recently invested billions in its new Meta Superintelligence Labs (MSL) unit. 'They haven't necessarily figured out what this AI is going to be used for.' She pointed to OpenAI's launch of GPT-5 last week, which many felt was underwhelming, as evidence the timeline to achieving AGI may be 'a little bit longer than we thought.' In the meantime, Pineau says there's a lot of room for more practical AI models to deliver leaps in productivity in different industries. A Canada native, Pineau said she's had her eye on Cohere since they were founded in 2019, and that she's excited to contribute to a company whose founders are based in her home country. Beyond the patriotism, Pineau feels the opportunity with Cohere is a good chance to venture beyond research. At FAIR, Pineau oversaw research teams working on projects that could take anywhere from 18 months to 10 years to deliver. Now, she'll be working within a much tighter timeline, as well as getting involved with customers and products. And even though Cohere has fewer resources than Meta, Pineau said she'll be more agile in her new role. Cohere's latest product is an AI agent platform dubbed North that enterprises and government agencies can deploy privately on their own infrastructure, an attractive notion for many of its customers, which are banks and federal organizations that handle highly sensitive data. That puts Cohere in competition with open-source providers like DeepSeek and Meta, whose models can also be run locally, but at a lower cost. Cohere is betting that by offering more support around its private deployments, it can beat out open models. Pineau said she's particularly interested in gearing more of Cohere's research around North, figuring out ways to develop AI agents in private and secure settings, and creating benchmarks to evaluate these systems. Pineau also said she's interested in exploring how networks of AI agents interact with each other in the real world. One immediate challenge for Pineau will be replacing Cohere's VP of AI Research, Sara Hooker, who announced her departure this week after several years of helping build the company's research program. Hiring an AI researcher of Hooker's caliber may be difficult in the current market given the skyrocketing demand for AI talent. But Pineau sees this as an opportunity to 'bring in a lot of talent,' noting that when she left Meta, several of her former colleagues suggested they'd follow her to a new AI lab. However, she emphasized that Cohere has a solid base of AI researchers, and that it's important to not just bring in anyone. 'Hiring a bunch of superstars doesn't necessarily make a superstar team,' said Pineau. 'It's really about how the people work together.' Of course, Meta's AI units today look very different compared with when Pineau was there just a few months ago. Over the summer, Mark Zuckerberg went on a recruiting spree, reportedly offering some of the industry's best AI researchers compensation packages north of $100 million to join MSL. That prompted OpenAI to also raise compensation for its star employees, thus making it quite difficult for smaller players to land top AI researchers. As Meta, OpenAI and Anthropic throw billions of dollars at their AI efforts, Cohere is trying to do more with less. For Pineau, that will mean making calculated research bets — the kind that can quickly turn into compelling products and keep the company in the race. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store